Category: InVivo Therapeutics Corp.Syndicate content

InVivo reports mixed results in spinal scaffold trial

May 18, 2015 by Mark Hollmer

InVivo Therapeutics reports mixed results from follow-up data on 2 patients implanted with its neuro-spinal scaffold to treat acute spinal cord injury.

InVivo reports mixed results in spinal scaffold trial

Gore pays $208.9 million in enhanced damages owed to C.R. Bard | Medtech legal news for the week of May 11, 2015

May 11, 2015 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Gore ponies up $209m in Bard loss; Siemens, China deny bribery report; InVivo Therapeutics, ex-CEO Reynolds escape shareholders' lawsuit

Gore ponies up $209m in Bard loss

May 6, 2015 by Brad Perriello

Gore ponies up $209m in Bard loss

InVivo Therapeutics, ex-CEO Reynolds escape shareholders' lawsuit

May 8, 2015 by Brad Perriello

A federal judge in Boston dismisses a shareholders lawsuit brought against InVivo Therapeutics and ex-CEO Frank Reynolds.

InVivo Therapeutics, ex-CEO Reynolds escape shareholders' lawsuit

InVivo hits the NASDAQ exchange

April 17, 2015 by Val Kennedy

Shares of InVivo Therapeutics are slated to begin trading today on the NASDAQ stock exchange.

InVivo shares to trade Friday on Nasdaq Capital Market

InVivo Therapeutics adds 4th clinical site

March 30, 2015 by Brad Perriello

InVivo Therapeutics adds the 4th site to a feasibility study of its biodegradable implant to treat acute spinal cord injuries.

InVivo Therapeutics adds 4th clinical site

InVivo adds 3rd site to clinical trial

March 26, 2015 by Mark Hollmer

InVivo Therapeutics adds a 3rd clinical site to a feasibility study of its biodegradable implant to treat acute spinal cord injuries.

InVivo adds 3rd site to clinical trial

InVivo Therapeutics readies reverse split ahead of NASDAQ listing

March 24, 2015 by Brad Perriello

InVivo Therapeutics readies a 1-for-4 reverse stock split ahead of a planned listing on the NASDAQ stock exchange.

InVivo Therapeutics readies reverse split ahead of NASDAQ listing